<DOC>
	<DOCNO>NCT01395433</DOCNO>
	<brief_summary>This bioequivalence study , regulatory requirement ensure comparable vivo performance , i.e . similarity term safety efficacy , administration two different dosage form escitalopram . All subject receive three separate dosage 20 mg escitalopram , 2 x 10 mg conventional dosage form ( Treatment A ) 2 x 10 mg new dosage form test ( Treatment B ) 1 x 20 mg new dosage form test ( Treatment C ) . Test treatment B C compare Treatment A , active comparator ( reference formulation ) .</brief_summary>
	<brief_title>Bioequivalence Study Comparing Two Formulations Escitalopram</brief_title>
	<detailed_description />
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Body mass index ( BMI ) 19 kg/m2 29 kg/m2 , inclusive The subject , opinion investigator , generally healthy base assessment medical history , physical examination , vital sign , electrocardiogram ( ECG ) , result haematology , clinical chemistry , urinalysis , serology , laboratory test The subject take disallowed medication within 1 week prior first dose investigational medicinal product ( IMP ) , within 5 halflives prior inclusion medication ingest , whichever long The subject significant history drug alcohol abuse The subject take investigational product within 3 month prior first dose IMP The subject history presence clinically significant immunological , cardiovascular , respiratory , metabolic , renal , hepatic , gastrointestinal , endocrinological , haematological , dermatological , venereal , neurological , psychiatric disease major disorder The subject history cancer , basal cell Stage 1 squamous cell carcinoma skin , remission least 5 year prior first dose IMP The subject history abdominal surgery ( exclude laparoscopic cholecystectomy uncomplicated appendectomy ) thoracic nonperipheral vascular surgery within 6 month prior first dose IMP The subject concurrent illness may affect particular target metabolism IMP The subject , opinion investigator , unlikely comply clinical study protocol unsuitable reason Other inclusion exclusion criterion may apply .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Assessing bioequivalence escitalopram dosage form</keyword>
</DOC>